Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 26, 2022; 10(9): 2660-2677
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2660
Role of metabolites derived from gut microbiota in inflammatory bowel disease
Lie Zheng, Xin-Li Wen, Sheng-Lei Duan
Lie Zheng, Xin-Li Wen, Sheng-Lei Duan, Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine, Xi’an 710003, Shaanxi Province, China
Author contributions: Zheng L and Duan SL performed to the writing, revising of the manuscript; Zheng L and Wen XL contributed to design this work, and performed overall supervision; Zheng L wrote and revised the paper.
Supported by Shaanxi Province Natural Science Basic Research Program-General Project, No: 2019JM-580 and 2021SF-314; Project of Shaanxi Administration of Traditional Chinese Medicine, No. 2019-ZZ-JC010; Shaanxi Provincial Hospital of Traditional Chinese Medicine, No. 2018-04.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sheng-Lei Duan, MD, Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine, No. 4 Xihuamen, Xi’an 710003, Shaanxi Province, China. 281930369@qq.com
Received: October 12, 2021
Peer-review started: October 12, 2021
First decision: December 3, 2021
Revised: December 12, 2021
Accepted: February 27, 2022
Article in press: February 27, 2022
Published online: March 26, 2022
Processing time: 161 Days and 0.7 Hours
Abstract

Over the past two decades, it is improved gut microbiota plays an important role in the health and disease pathogenesis. Metabolites, small molecules produced as intermediate or end products of microbial metabolism, is considered as one of the major interaction way for gut microbiota with the host. Bacterial metabolisms of dietary substrates, modification of host molecules or bacteria are the major source of metabolites. Signals from microbial metabolites affect immune maturation and homeostasis, host energy metabolism as well as mucosal integrity maintenance. Based on many researches, the composition and function of the microbiota can be changed, which is also seen in the metabolite profiles of patients with inflammatory bowel disease (IBD). Additionally, some specific classes of metabolites also can trigger IBD. In this paper, definition of the key classes of microbial-derived metabolites which are changed in IBD, description of the pathophysiological basis of association and identification of the precision therapeutic modulation in the future are the major contents.

Keywords: Inflammatory bowel disease, Microbial metabolites, Short chain fatty acids, Bile acids, Tryptophan

Core Tip: In the gastrointestinal tract of the human, a variety of microorganisms such as bacteria, fungi, viruses, archaea and protozoa are collected and considered as a community, containing a genome, suitable to the environment and the host. Microbiome, with wide functions, can ferment dietary fibres, defence pathogen, synthesize vitamin and promote immune maturation and metabolic homeostasis, which indicates microbiome is deeply integrated with human biology. However, because gut microbiota is associated with ancestral diet high in fibre, the dietary alteration resulted from western diet causes maladaptive change for this association, and products of microbial metabolism exist at a nexus between host and microbiome.